文献
J-GLOBAL ID:201702241748295009
整理番号:17A1718365
不十分に制御された1型糖尿病(DEPICT 1)患者におけるダパグリフロジンの有効性と安全性:多施設二重盲検,第3相無作為化比較対照試験の24週間の結果【Powered by NICT】
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
著者 (11件):
Dandona Paresh
(Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA)
,
Mathieu Chantal
(Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium)
,
Phillip Moshe
(Schneider Children’s Medical Center of Israel, Institute for Endocrinology & Diabetes, Petah Tikva, Israel)
,
Phillip Moshe
(Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel)
,
Hansen Lars
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Griffen Steven C
(JDRF, New York, NY, USA)
,
Tschope Diethelm
(Department for Endocrinology, Diabetology & Gastroenterology, Heart and Diabetes Centre, Bad Oeynhausen, Germany)
,
Tschope Diethelm
(Ruhr University Bochum, Bochum, Germany)
,
Thoren Fredrik
(AstraZeneca, Molndal, Sweden)
,
Xu John
(AstraZeneca, Gaithersburg, MD, USA)
,
Langkilde Anna Maria
(AstraZeneca, Molndal, Sweden)
資料名:
Lancet Diabetes & Endocrinology
(Lancet Diabetes & Endocrinology)
巻:
5
号:
11
ページ:
864-876
発行年:
2017年
JST資料番号:
W3110A
ISSN:
2213-8587
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)